378 related articles for article (PubMed ID: 35724821)
1. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
Muinos-Bühl A; Rombo R; Janzen E; Ling KK; Hupperich K; Rigo F; Bennett CF; Wirth B
Neurobiol Dis; 2022 Sep; 171():105795. PubMed ID: 35724821
[TBL] [Abstract][Full Text] [Related]
2. CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis.
Janzen E; Mendoza-Ferreira N; Hosseinibarkooie S; Schneider S; Hupperich K; Tschanz T; Grysko V; Riessland M; Hammerschmidt M; Rigo F; Bennett CF; Kye MJ; Torres-Benito L; Wirth B
Brain; 2018 Aug; 141(8):2343-2361. PubMed ID: 29961886
[TBL] [Abstract][Full Text] [Related]
3. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
[TBL] [Abstract][Full Text] [Related]
4. Long-Term
Muiños-Bühl A; Rombo R; Ling KK; Zilio E; Rigo F; Bennett CF; Wirth B
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835624
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice.
Strathmann EA; Peters M; Hosseinibarkooie S; Rigo FW; Bennett CF; Zaworski PG; Chen KS; Nothnagel M; Wirth B
PLoS One; 2018; 13(9):e0203398. PubMed ID: 30188931
[TBL] [Abstract][Full Text] [Related]
6. The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype.
Hosseinibarkooie S; Peters M; Torres-Benito L; Rastetter RH; Hupperich K; Hoffmann A; Mendoza-Ferreira N; Kaczmarek A; Janzen E; Milbradt J; Lamkemeyer T; Rigo F; Bennett CF; Guschlbauer C; Büschges A; Hammerschmidt M; Riessland M; Kye MJ; Clemen CS; Wirth B
Am J Hum Genet; 2016 Sep; 99(3):647-665. PubMed ID: 27499521
[TBL] [Abstract][Full Text] [Related]
7. Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis.
Riessland M; Kaczmarek A; Schneider S; Swoboda KJ; Löhr H; Bradler C; Grysko V; Dimitriadi M; Hosseinibarkooie S; Torres-Benito L; Peters M; Upadhyay A; Biglari N; Kröber S; Hölker I; Garbes L; Gilissen C; Hoischen A; Nürnberg G; Nürnberg P; Walter M; Rigo F; Bennett CF; Kye MJ; Hart AC; Hammerschmidt M; Kloppenburg P; Wirth B
Am J Hum Genet; 2017 Feb; 100(2):297-315. PubMed ID: 28132687
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
[TBL] [Abstract][Full Text] [Related]
9. Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy.
Aslesh T; Yokota T
Cells; 2022 Jan; 11(3):. PubMed ID: 35159227
[TBL] [Abstract][Full Text] [Related]
10. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
Wood MJA; Talbot K; Bowerman M
Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
[TBL] [Abstract][Full Text] [Related]
11. Motor unit recovery following Smn restoration in mouse models of spinal muscular atrophy.
Comley LH; Kline RA; Thomson AK; Woschitz V; Landeros EV; Osman EY; Lorson CL; Murray LM
Hum Mol Genet; 2022 Sep; 31(18):3107-3119. PubMed ID: 35551393
[TBL] [Abstract][Full Text] [Related]
12. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
Chen TH
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694
[TBL] [Abstract][Full Text] [Related]
13. Nusinersen ameliorates motor function and prevents motoneuron Cajal body disassembly and abnormal poly(A) RNA distribution in a SMA mouse model.
Berciano MT; Puente-Bedia A; Medina-Samamé A; Rodríguez-Rey JC; Calderó J; Lafarga M; Tapia O
Sci Rep; 2020 Jul; 10(1):10738. PubMed ID: 32612161
[TBL] [Abstract][Full Text] [Related]
14. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.
Hua Y; Sahashi K; Rigo F; Hung G; Horev G; Bennett CF; Krainer AR
Nature; 2011 Oct; 478(7367):123-6. PubMed ID: 21979052
[TBL] [Abstract][Full Text] [Related]
15. Plastin 3 Expression Does Not Modify Spinal Muscular Atrophy Severity in the ∆7 SMA Mouse.
McGovern VL; Massoni-Laporte A; Wang X; Le TT; Le HT; Beattie CE; Rich MM; Burghes AH
PLoS One; 2015; 10(7):e0132364. PubMed ID: 26134627
[TBL] [Abstract][Full Text] [Related]
16. Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic ∆7SMA mice.
Kray KM; McGovern VL; Chugh D; Arnold WD; Burghes AHM
Neurobiol Dis; 2021 Nov; 159():105488. PubMed ID: 34425216
[TBL] [Abstract][Full Text] [Related]
17. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration.
Arnold WD; Duque S; Iyer CC; Zaworski P; McGovern VL; Taylor SJ; von Herrmann KM; Kobayashi DT; Chen KS; Kolb SJ; Paushkin SV; Burghes AH
PLoS One; 2016; 11(12):e0167077. PubMed ID: 27907033
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.
Passini MA; Bu J; Richards AM; Kinnecom C; Sardi SP; Stanek LM; Hua Y; Rigo F; Matson J; Hung G; Kaye EM; Shihabuddin LS; Krainer AR; Bennett CF; Cheng SH
Sci Transl Med; 2011 Mar; 3(72):72ra18. PubMed ID: 21368223
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides targeting the SMN2 promoter region enhance SMN2 expression in spinal muscular atrophy cell lines and mouse model.
Wang J; Bai J; OuYang S; Wang H; Jin Y; Peng X; Ge X; Jiao H; Zou J; He C; Xiao P; Song F; Qu Y
Hum Mol Genet; 2022 May; 31(10):1635-1650. PubMed ID: 34888619
[TBL] [Abstract][Full Text] [Related]
20. An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy.
Li Y; Zeng H; Wei Y; Ma X; He Z
Hum Gene Ther; 2023 Mar; 34(5-6):180-191. PubMed ID: 36762938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
